The company struck a deal with the U.S. Justice Department and the Federal Trade Commission to resolve charges related to the marketing and sales of Suboxone Film.
Federal prosecutors claimed that Reckitt “illegally obtained billions of dollars in revenue” by tricking healthcare providers into believing that Suboxone is safer and less susceptible to abuse than similar drugs although its active ingredient is an opioid.
The settlement is the largest financial penalty issued that’s tied to the opioid crisis, according to the report.
Suboxone film is used to treat addiction to other drugs like heroin. It’s made by Reckitt’s former pharma arm, Indivior, which became a stand-alone company in 2014.
More articles on pharmacy:
Judge blocks HHS rule requiring drug prices in TV ads
Nation’s 1st prescription drug affordability board goes into effect
11 healthcare pharma leaders offer advice on controlling drug spend
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
